Table IV.
The clinical prospects of autophagy activators and inhibitors.
Drugs | Diseases | Functions | Possible mechanism | In human/animal/cell model | Reference |
---|---|---|---|---|---|
Autophagy activators | |||||
Rapamycin | Breast cancer | Inhibits proliferation of the endoplasmic reticulum-positive MCF-7 cell line | Rapidly stimulate mTOR non-specifically after medium replacement | MCF-7 breast cancer cell line | Chang et al. (2007) |
Transplanted tumors | Inhibits tumor growth at any stage of development | – | – | Eng et al. (1984) | |
Pancreatic cancer | Regulates cell growth and cyclin D1 expression | Constitutively actives FRAP-p70s6K pathway and inhibits cyclin D1 expression | MiaPaCa-2 and Panc-1 human pancreatic cancer cells and a pancreatic cancer tissue sample | Grewe et al. (1999) | |
Vascular disease | Reduces vascular inflammation | Suppresses macrophage proliferation | Mice | Boada et al. (2020) | |
Type 2 diabetes | Improves insulin resistance and hepatic steatosis | Enhances autophagy by the inhibition of mTOR pathway | T2DM rats | Zhou and Ye (2018) | |
Myotrophic lateral sclerosis | Reduces neuronal loss and TDP43 inclusions; expands regulatory T lymphocytes with slow progression in ALS patients | Activates autophagy | Four human NB cell lines (AS, NGP, BE2, and KCNR); mice carrying xenograft NB tumors | Mandrioli et al. (2018) | |
Facial angiofibromas | Appears effective and safe for treatment of TSC-related facial angiofibromas | – | TB3 cells | Koenig et al. (2018) | |
Improves ovarian function and reproductive longevity | – | – | Hine (2017) | ||
Perifosine | Neuroblastoma | increases apoptosis and inhibits neuroblastoma tumor cell growth in vitro and in vivo | Decreases AKT phosphorylation | Four human NB cell lines (AS, NGP, BE2, and KCNR); mice carrying xenograft NB tumors | Li et al. (2010) |
Neuroblastoma | Attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance | Inhibits AKT | TB3 cells | Li et al. (2011) | |
Metformin | Glioblastoma | Inhibits growth of human glioblastoma cells and enhances therapeutic response | Activates AMPK, Redd1 and inhibits mTOR pathway | Four human glioblastoma cell lines, U87 (ATCC HTB-14), LN18 (ATCC CRL-2610), U251 and SF767 | Sesen et al. (2015) |
Metformin and Rapamycin | Prostate tumors | Inhibits progression of prostatic intraepithelial neoplasia lesions to adenocarcinomas in the ventral prostate | Down-regulates mTORC1 signaling | HiMyc mice | Saha et al. (2015) |
Metformin | Reproductive health, gynecological cancer | Inhibits progression of prostatic intraepithelial neoplasia lesions to adenocarcinomas in the ventral prostate | Upstream activation of AMPK, resulting in inhibition of the mTOR pathway. | HiMyc mice | Saha et al. (2015) |
Autophagy inhibitors | |||||
Bafilomycin A1 | Pediatric B-cell acute lymphoblastic leukemia | Inhibits and kills pediatric B-cell acute lymphoblastic leukemia cells | Targets both autophagy and apoptosis by disassociating the Beclin 1–Vps34 complex | – | Yuan et al. (2015) |
Microcephaly | Inhibits ZIKV entry and prevents the spread of the infection by interfering with viral maturation | Inhibits V-ATPase | – | Sabino et al. (2019) | |
Tongue squamous cell carcinoma | Increases the sensitivity of tongue squamous cell carcinoma cells to cisplatin | Inhibition of the lysosomal uptake of platinum ions but not autophagy | – | Chu et al. (2018) | |
Chloroquine | Breast cancer | Enhances the efficacy of tumor cell killing by combination with chemotherapeutic drugs and radiation | – | – | Maycotte et al. (2012) |
Colon cancer | Enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration | Anti-cancer effect of 5-FU via cell cycle inhibition | Human colon cancer DLD-1 cells | Choi et al. (2012) | |
3-MA or chloroquine | Glioblastomas | Improves the efficacy of curcumin/temozolomide combination therapy | Increases apoptosis | C6, U251MG and U87MG cell lines; primary astrocytes | Zanotto-Filho et al. (2015) |
Malignant gliomas | Enhances temozolomide cytotoxicity | Blocks autophagy and triggers endoplasmic reticulum stress, increasing the chemosensitivity of glioma cells to temozolomide | Subcutaneously implanted U87MG tumors from mice | Golden et al. (2014) | |
Glioma | Potentiates temozolomide cytotoxicity | Inhibits mitochondrial autophagy | Tumor cells derived from a glioblastoma patient and human U87-MG glioblastoma cells | Hori et al. (2015) | |
Hydroxy chloroquine | Advanced solid tumors and melanoma | Augments cell death in preclinical models | Blocks autophagy | – | Rangwala et al. (2014a,b) |
Lucanthone | Breast cancer | Induces apoptosis via cathepsin D accumulation and enhances vorinostat-mediated cell death in breast cancer models. | Induces lysosomal membrane permeabilization | p53(+/+) and p53(−/−) HCT116 cells | Carew et al. (2011) |
Wortmannin | Ovarian cancer | Enhances cisplatin-induced apoptosis | Activates PI3K/Akt signaling pathway | A2780 ovarian adenocarcinoma cell line and A2780cis | Zhao et al. (2014) |
3-MA, 3-methylade nine; AKT, protein kinase B; ALS, amyotrophic lateral sclerosis; AMPK, AMP-activated protein kinase; MCF-7 cells, human breast cancer cell lines; mTOR, mammalian target of rapamycin; NB tumor, neuroblastoma; T2DM rat, type 2 diabetes mellitus rat; TrkB, neurotrophic receptor tyrosine kinase 2; TSC, tuberous sclerosis complex; ZIKV, Zika virus.